Aspect Imaging has signed an agreement with Cage Chemicals to develop and manufacture Aspect's PhenoQuant line of contrast agents for preclinical research.
The Molecular Imaging Center at the University of Turin in Italy will also develop scientific preclinical applications and protocols to support the use of the agents for molecular imaging using Aspect's M2 compact high-performance MRI system.
M2 has no magnetic fringe field and costs less than traditional MRI systems.
